The foremost obstacle to curing Alzheimer's disease has been a lack of understanding of the disease. Understanding per se was a sufficient obstacle, but getting investors to both understand and then support an effective clinical intervention has taken years and perhaps the patience of a saint. In 2021, we see the "proper time and place" for that intervention is upon our horizon. The fundamental mechanisms involved have been clearly delineated in the literature. Our investment partners are now ready to move ahead as we push forward to human trials. Over the past year, we have not only published a clear explanation of the model – and how we can intervene effectively – we have also added gravitas and credibility to our program through those we have brought onto our scientific and clinical advisory boards.
Nor are those the only current changes.
We have engaged Kim Gannon, PhD, whose expertise in biotechnology, gene therapy, clinical trials, and Alzheimer's disease make her a valuable addition to our team. We are delighted to have Kim's support and her hands-on knowledge behind our vision as we move ahead. We have also engaged two other globally-known experts. Both have demonstrated success in gene therapy, encompassing manufacturing, preclinical studies, regulatory submissions and clinical trials. Together, these new additions to our team, along with the rest of us at Telocyte, are working toward a rigorously verified treatment for Alzheimer's disease.
Our first animal study later this year will give us a chance to not only refine the technical aspects of our therapy, but will help ensure we have the safest and most effective intervention for our planned human trial. In addition, this study will help gather the data we need to obtain proof of concept in a large animal model, demonstrate widespread brain distribution of our therapeutic, and help guide dose selection for future studies, including the clinical trial. Data from this study will solidify our intellectual property position, generate excitement for and confirmation of our approach and facilitate additional funding necessary for successful human trials.
If you would like to understand more about our approach, we will be improving our website in the next month or so, including videos such as this 3-minute animation, which explains how Alzheimer's works and how we can intervene clinically. If you prefer a longer (35 minute) presentation, you may want to view this lecture, given at a recent neurology conference. Our primary mission, however, resides in neither a website nor a video. Our mission remains a more critical, practical, and difficult goal, driven by compassion: we intend to cure Alzheimer's disease.
We see the "proper time and place" as within the reach of here and now.